Price T Rowe Associates Inc Repligen Corp Transaction History
Price T Rowe Associates Inc
- $812 Billion
- Q1 2025
A detailed history of Price T Rowe Associates Inc transactions in Repligen Corp stock. As of the latest transaction made, Price T Rowe Associates Inc holds 7,566,093 shares of RGEN stock, worth $957 Million. This represents 0.12% of its overall portfolio holdings.
Number of Shares
7,566,093
Previous 7,136,054
6.03%
Holding current value
$957 Million
Previous $1.03 Billion
6.27%
% of portfolio
0.12%
Previous 0.12%
Shares
18 transactions
Others Institutions Holding RGEN
# of Institutions
494Shares Held
57.6MCall Options Held
75.6KPut Options Held
521K-
Black Rock Inc. New York, NY7.57MShares$957 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.08MShares$643 Million0.01% of portfolio
-
State Street Corp Boston, MA1.69MShares$214 Million0.01% of portfolio
-
Invesco Ltd. Atlanta, GA1.67MShares$212 Million0.04% of portfolio
-
Champlain Investment Partners, LLC Burlington, VT1.46MShares$185 Million1.43% of portfolio
About REPLIGEN CORP
- Ticker RGEN
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Instruments & Supplies
- Shares Outstandng 55,491,200
- Market Cap $7.02B
- Description
- Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products....